 Melevodopa | |
 Carbidopa | |
| Combination of | |
|---|---|
| Melevodopa | Dopamine receptor agonist |
| Carbidopa | Aromatic L-amino acid decarboxylase inhibitor |
| Clinical data | |
| Trade names | Sirio |
| Other names | Carbidopa/melevodopa; Levodopa methyl ester/carbidopa; CHF-1512; CHF1512; CNP-1512; CNP1512; GT-1512; GT1512; V-1512; V1512 |
| Routes of administration | Oral[1] |
Melevodopa/carbidopa, sold under the brand name Sirio, is a combination of melevodopa, a prodrug of the dopamine precursor and hence non-selective dopamine receptor agonist levodopa (L-DOPA), and carbidopa, a peripherally selective aromatic L-amino acid decarboxylase (AAAD) inhibitor, which is used in the treatment of Parkinson's disease in Italy.[2][3][4][5][1] It is taken orally in the form of tablets.[1][4]
- ^ a b c "Melevodopa: Uses, Interactions, Mechanism of Action". DrugBank Online. 1 April 2015. Retrieved 27 September 2024.
- ^ "Melevodopa/carbidopa". AdisInsight. Springer Nature Switzerland AG. 23 September 2021. Retrieved 27 September 2024.
- ^ Stocchi F, Marconi S (July 2010). "Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio)". Clinical Neuropharmacology. 33 (4): 198–203. doi:10.1097/WNF.0b013e3181de8924. PMID 20414107.
- ^ a b Antonini A, Chaudhuri KR, Martinez-Martin P, Odin P (February 2010). "Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease". CNS Drugs. 24 (2): 119–129. doi:10.2165/11310940-000000000-00000. PMID 20088619.
- ^ Hengartner D, Fernandez HH (February 2019). "The next chapter in symptomatic Parkinson disease treatments". Parkinsonism & Related Disorders. 59: 39–48. doi:10.1016/j.parkreldis.2019.01.002. PMID 30661840.